BNTX BioNTech SE
Price Chart
Executive Summary
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival across all HER2 expression levels, with a manageable safety profile. The data support the drug's potential in a high-unmet-need population, including those with prior checkpoint inhibitor exposure.
Actionable Insight
Trastuzumab pamirtecan represents a potentially practice-changing therapy in recurrent endometrial cancer, a space with few effective options. With Breakthrough Therapy designation and strong Phase 2 data across HER2 expression levels, the path toward BLA filing in 2026 enhances near-term catalyst potential. Traders should monitor upcoming regulatory interactions and Phase 3 readouts, particularly DYNASTY-Breast02 later this year.
Key Facts
- Phase 2 cohort of 145 patients with advanced HER2-expressing endometrial cancer met primary endpoint of objective response rate (ORR).
- Confirmed ORR was 47.9% in centrally tested patients (n=96), with 49.3% in those previously treated with checkpoint inhibitors.
- Median progression-free survival was 8.1 months (95% CI: 5.5, 11.8) in centrally tested patients.
- Trastuzumab pamirtecan showed activity across all HER2 expression levels (IHC1+, IHC2+, IHC3+) and in real-world populations including those with visceral metastases.
- Safety profile was manageable; grade ≥3 treatment-related adverse events occurred in 46.9% of patients, with 4.8% experiencing grade ≥3 ILD/pneumonitis.
- FDA has granted Fast Track and Breakthrough Therapy designations for this indication; BLA submission planned in 2026 pending regulatory feedback.
- Global Phase 3 trial (Fern-EC-01) is ongoing, with plans to file BLA subject to FDA input.
Financial Impact
High-value oncology pipeline advancement with registrational potential; could expand BNTX's market beyond mRNA into targeted cancer therapies.
Risk Factors
- Phase 2 data may not be replicated in larger Phase 3 trials.
- Safety signals, including 4.8% grade ≥3 ILD/pneumonitis, could impact regulatory or commercial acceptance.
- Dependence on successful collaboration with DualityBio for development and commercialization.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $88.08 awaiting T+5 | awaiting T+5 | — | $86.50 (−1.79%) |
|
Jun 1, 2026
8d ago
|
6-K
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $86.50 (−5.67%) |
|
May 30, 2026
10d ago
|
Press Release
| $91.70 $88.08 | ▼ −3.95% | ▼ −1.20% | $86.50 (−5.67%) |
|
May 22, 2026
18d ago
|
6-K
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.15% | $86.50 (−6.12%) |
|
May 22, 2026
18d ago
|
Press Release
| $92.14 $91.70 | ▼ −0.48% | ▼ −2.14% | $86.50 (−6.12%) |
|
May 15, 2026
25d ago
|
6-K
| $88.85 $92.25 | ▲ +3.83% | ▲ +2.21% | $86.50 (−2.64%) |
|
May 7, 2026
4w ago
|
6-K
| $93.02 $92.23 | ▼ −0.85% | ▼ −2.35% | $86.50 (−7.01%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▲ +1.93% | ▲ +3.91% | $86.50 (+9.42%) |
|
May 5, 2026
5w ago
|
6-K
| $95.50 $93.66 | ▼ −1.93% | ▼ −3.91% | $86.50 (−9.42%) |
|
May 5, 2026
5w ago
|
Press Release
| $95.50 $93.34 | ▼ −2.26% | ▼ −4.25% | $86.50 (−9.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access